Product Overview
[Drug Name]
Generic Name: Candesartan Cilexetil Tablets
Trade Name: Weiliya Candesartan Cilexetil Tablets 4mg*14 Tablets
Pinyin Full Code: KanDiShaTanZhiPian
[Main Ingredients]
The main ingredient of this product is candesartan cilexetil.
[Properties]
This product is a white tablet.
[Indications/Main Functions]
It is used to treat essential hypertension. This product can be used alone or in combination with other antihypertensive drugs.
[Specifications]
4mg*14 tablets (Weilya)
[Usage and Dosage]
Oral, generally once a day for adults, 4-8mg per time, the dose can be increased to 12mg if necessary.
[Adverse Reactions]
Serious adverse reactions (incidence unknown): (1) Angioedema: Angioedema with symptoms of edema of the face, lips, tongue, pharynx, larynx, etc. should be carefully observed. If abnormalities are found, stop taking the drug and take appropriate measures. (2) Syncope and loss of consciousness: Excessive blood pressure reduction may cause syncope and temporary loss of consciousness. In this case, the drug should be stopped and appropriate treatment should be implemented. In particular, patients undergoing hemodialysis, patients undergoing strict salt restriction therapy, and patients who have recently started taking diuretic antihypertensive drugs may experience a rapid drop in blood pressure. Therefore, these patients should start with a lower dose of this drug. If it is necessary to increase the dose, the patient's condition should be closely observed and the dosage should be increased slowly. (3) Acute renal failure: Acute renal failure may occur. The patient's condition should be closely observed. If abnormalities are found, the drug should be stopped and appropriate treatment should be implemented. (4) Patients with hyperkalemia: In view of the possibility of hyperkalemia, the patient's condition should be closely observed. If abnormalities are found, the drug should be stopped and appropriate treatment should be implemented. (5) Deterioration of liver function or jaundice: In view of the possibility of liver dysfunction or jaundice with elevated AST (GOT), ACT (GTP), etc., the patient's condition should be closely observed. If abnormalities are found, the drug should be stopped and appropriate treatment should be implemented. (6) Agranulocytosis: Agranulocytosis may occur and the patient's condition should be closely monitored. If abnormalities are found, the drug should be stopped and appropriate treatment should be implemented. (7) Rhabdomyolysis: Symptoms such as myalgia, weakness, increased CK, and myosin in the blood and urine may occur. If the above symptoms occur, the drug should be stopped and appropriate treatment should be implemented. (8) Interstitial pneumonia: Interstitial pneumonia accompanied by fever, cough, dyspnea, and abnormal chest X-ray examination may occur. If the above symptoms occur, the drug should be stopped and appropriate treatment should be implemented, such as treatment with corticosteroids.
[Contraindications]
1. Patients with a history of allergy to the ingredients of this preparation.
2. Pregnant or potentially pregnant women.
3. Patients with severe liver or kidney dysfunction or cholestasis.
[Drug Interactions]
Be careful when using this product together (caution should be exercised when using this product together). This product has no significant interactions with drugs such as glyburide, nimodipine, digoxin, warfarin, and hydrochlorothiazide. There is also no significant interaction in the case of oral contraceptives in healthy subjects.
[Precautions]
1. Use with caution (this product should be used with caution in the following patients): (1) Patients with bilateral or unilateral renal arteries (see 2 Important Basic Precautions). (2) Patients with hyperkalemia (see 2 Important Basic Precautions). (3) Patients with liver dysfunction (this product may worsen liver function. In addition, it is speculated that the clearance rate of the active metabolite candesartan is reduced, so it should be taken at a low dose and used with caution). (4) Patients with severe renal dysfunction (due to excessive blood pressure reduction, this product may worsen renal function, so it should be taken once a day, starting with 2 mg, and used with caution). (5) Patients with a history of drug allergy. (6) Elderly patients). (7) Kidney transplantation: There is no experience with this product in patients who have recently undergone kidney transplantation. (8) Stenosis of the great arteries and left atrioventricular valves (obstructive cardiomyopathy): Patients using other vasodilators, patients with hemodynamically relevant stenosis of the great arteries or left atrioventricular valves or obstructive cardiomyopathy should use this drug with caution. (9) Mild to moderate hyperadrenocorticism: Patients with mild to moderate hyperadrenocorticism usually do not respond to antihypertensive drugs that inhibit the renin-angiotensin and aldosterone systems, so this drug is not recommended. 2. Important basic precautions (1) Patients with bilateral or unilateral renal artery stenosis who take drugs that affect the renin-angiotensin-aldosterone system may increase the risk of renal function due to the reduction of renal blood flow and filtration pressure. Unless it is considered necessary for treatment, this drug should be avoided as much as possible. (2) Because it may aggravate hyperkalemia, patients with hyperkalemia should avoid taking this drug as much as possible unless it is considered necessary for treatment. In addition, patients with uncontrolled diabetes and renal dysfunction should pay close attention to their blood potassium levels because these patients are prone to developing hyperkalemia. (3) Since this preparation may cause a sharp drop in blood pressure, it should be started with a low dose, especially for the following patients. When increasing the dose, the patient's condition should be carefully observed and the dosage should be increased slowly. A. Patients undergoing hemodialysis. B. Patients undergoing strict salt restriction therapy. C. Patients taking diuretic antihypertensive drugs (especially those who have recently started taking diuretic antihypertensive drugs). (4) Due to the antihypertensive effect, dizziness and staggering may occur. Therefore, caution should be exercised when performing high-altitude work or driving a vehicle. (5) It is best to stop taking the drug 24 hours before surgery. (6) When delivering the drug: The drug packaged in the PTP sheet should be taken after it is removed from the PTP sheet (there have been reports of accidental ingestion of the hard sharp corners of the PTP sheet, which may pierce the esophageal mucosa and cause perforation, leading to serious complications such as mediastinitis).
[Drugs for children]
The safety of this drug for children has not been determined (no experience).
[Drugs for elderly patients]
It is generally believed that blood pressure should not be excessively lowered in the elderly (it may cause cerebral infarction, etc.). It should be taken with caution while the patient is under observation. For elderly patients with normal liver and kidney function, the starting dose is 4 mg. For patients with renal or hepatic impairment, a starting dose of 2 mg is recommended. The dose should be adjusted based on the patient's condition.
[Overdose]
According to pharmacological studies, overdose primarily manifests as symptomatic hypotension and dizziness. If symptomatic hypotension occurs, symptomatic treatment and vital signs monitoring are essential. The patient should be placed in a supine position with the feet elevated and the head down. If necessary, isotonic saline should be injected to increase plasma volume. If the above measures do not correct the condition, sympathomimetic drugs can be administered.
[Pharmacology and Toxicology]
Candesartan cilexetil is rapidly hydrolyzed in vivo to its active metabolite, candesartan. Candesartan is a selective angiotensin I receptor (AT1) antagonist. It binds to AT1 receptors on vascular smooth muscle, antagonizing the vasoconstrictive effects of angiotensin I, thereby reducing peripheral vascular resistance. It is also believed that candesartan may exert a certain antihypertensive effect by inhibiting adrenal aldosterone secretion. Candesartan does not inhibit kininase I and does not affect bradykinin degradation. Experiments conducted on patients with hypertension showed that repeated use of this product can lead to increased plasma renin activity, angiotensin 1 concentration and angiotensin-inter-concentration; continuous use of 2-8 mg of this product once a day can reduce systolic and diastolic blood pressure, left ventricular myocardial weight and peripheral vascular resistance, but has no significant effect on cardiac output, ejection fraction, renal vascular resistance, renal blood flow, and glomerular filtration rate; it has no effect on cerebral blood flow in patients with primary hypertension who have cerebrovascular disorders.
